^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SIBP-04 (bevacizumab biosimilar)

    i
    Other names: SIBP-04, SIBP 04, SIBP-A04
    Company:
    Sinopharm
    Drug class:
    VEGF-A inhibitor, Angiogenesis inhibitor
    Related drugs:
    11ms
    A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects (clinicaltrials.gov)
    P1, N=88, Completed, Shanghai Institute Of Biological Products | Unknown status --> Completed
    Trial completion
    |
    Avastin (bevacizumab) • SIBP-04 (bevacizumab biosimilar)
    11ms
    A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=512, Completed, Shanghai Institute Of Biological Products | Recruiting --> Completed | Trial completion date: Sep 2022 --> Jan 2023
    Trial completion • Trial completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ROS1 positive
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • SIBP-04 (bevacizumab biosimilar)
    over1year
    Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial. (PubMed, J Cancer Res Clin Oncol)
    Bevacizumab combined with chemotherapy significantly prolonged the PFS and OS of advanced nsqNSCLC patients with EGFR mutation.
    Clinical • P3 data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR expression • EGFR wild-type
    |
    carboplatin • paclitaxel • SIBP-04 (bevacizumab biosimilar)
    over2years
    A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=512, Recruiting, Shanghai Institute Of Biological Products
    New P3 trial • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ROS1 positive
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • SIBP-04 (bevacizumab biosimilar)